CCR Clinical Trials at NIH: Clinical Research: Search for Clinical Trials at NIH

The NCI Center for Cancer Research (CCR) conducts more than 150 cancer clinical trials at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. Cancer clinical trials that take place at the NIH Clinical Center are open to patients with cancer, regardless of where they live in the United States.

Go to Search Page

There are 31 clinical trials at NIH that match your search criteria

Cancer by body location/system: Pediatric Cancers

Trial and Protocol Number Pediatric Cancers	Principal Investigator	Referral Contact
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase 2.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung (A Sarcoma Alliance for Research Through Collaboration [SARC] Study) NCI-09-C-0104	Lee J. Helman 301-496-4257	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar^®) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas NCI-08-C-0180	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of VEGF Trap (NSC #724770, IND #100137) in Children With Refractory Solid Tumors (Children’s Oncology Group Study ADVL0714) NCI-08-C-0179	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Pilot Study of Imatinib Mesylate in Children and Adults With Sclerotic Skin Changes of Chronic Graft-Versus-Host Disease NCI-08-C-0148	Edward Cowen 301-496-4299	Susan Booher 301-402-1474 boohers@mail.nih.gov
A Phase II Trial of Peginterferon Alpha-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic, or Life-Threatening Plexiform Neurofibromas NCI-08-C-0130	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Children, Adolescents, and Young Adults With Refractory CD22+ Acute Lymphoblastic Leukemia (ALL) or Non-Hodgkin’s Lymphoma (NHL) NCI-08-C-0123	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type I Related Plexiform Neurofibromas NCI-08-C-0096	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
SARC Global Collaboration: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing’s Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma, and Other Sarcomas NCI-08-C-0080	Lee J. Helman 301-496-4257	Pediatric Oncology 1-877-624-4878 (Toll free)
A Pilot Trial of WT1 Peptide-Loaded Allogeneic Dendritic Cell Vaccine and Donor Lymphocyte Infusion for WT1-Expressing Hematologic Malignancies NCI-08-C-0051	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer NCI-08-C-0007	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors NCI-07-C-0220 (A Cooperative Group Study: ADVL0612)	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Pilot Study of Tumor Vaccination in Patients With Neuroblastoma and Pediatric Sarcomas and Altered T-Cell Homeostasis NCI-07-C-0206	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I/II Trial of Vandetanib (ZD6474, ZACTIMA) in Children and Adolescents With Hereditary Medullary Thyroid Cancer NCI-07-C-0189	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of BMS-354825 (Dasatinib) in Children With Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia (A Cooperative Group Study) NCI-07-C-0166	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase II Study of ABT-751, an Orally Bioavailable Tubulin Binding Agent, in Children With Relapsed or Refractory Neuroblastoma NCI-07-C-0074	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Trial and Pharmacokinetic Study of Trabectedin (YONDELIS^®, ET-743) in Children and Adolescents With Relapsed or Refractory Solid Tumors NCI-07-C-0054	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial of Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients With Refractory Pediatric Solid Tumors NCI-07-C-0040	Crystal Mackall 301-402-5940	Pediatric Oncology 1-877-624-4878 (Toll free)
A Phase I Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor BAY 43-9006 (Sorafenib) in Children With Refractory Solid Tumors or Refractory Leukemias NCI-06-C-0233	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors NCI-06-C-0219	Katherine E. Warren 301-496-4256	Robyn Bent 301-496-8009 rbent@mail.nih.gov
Phase I Trial of Cediranib (AZ2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents With Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia NCI-06-C-0152	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors NCI-06-C-0043	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman’s Disease With Laboratory and Clinical Correlates of Disease Activity NCI-04-C-0275	Robert Yarchoan 301-496-8959	Karen Aleman 301-496-8959 1-800-243-2732 ext. 4 (Toll Free) alemank@mail.nih.gov
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas NCI-04-C-0173	Wyndham H. Wilson 301-435-2415	Peggy Shovlin 301-594-6597 mshovlin@mail.nih.gov
Phase II Study of Sequential Gemcitabine and Docetaxel in Patients With Recurrent Osteosarcoma or Ewing’s Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma NCI-04-C-0001	Elizabeth Fox 301-402-6641	Pediatric Oncology 1-877-624-4878 (Toll free)
Comparative Trial of Pediatric CNS Tumor Activity as Assessed by PET Imaging and Proton Magnetic Resonance Spectroscopy Imaging (MRSI) NCI-03-C-0278	Katherine E. Warren 301-496-4256	Robyn Bent 301-496-8009 rbent@mail.nih.gov
Cancer Risk in Xeroderma Pigmentosum Heterozygotes NCI-02-C-0313	Kenneth H. Kraemer 301-496-9033	Deborah Tamura 301-594-5030 tamurad@mail.nih.gov
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas NCI-02-C-0259	Kristin Baird 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors and Leukemias NCI-02-C-0031	Brigitte Widemann 301-496-7387	Pediatric Oncology 1-877-624-4878 (Toll free)
Pilot Study of Non-Myeloablative, HLA-matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies NCI-01-C-0125	Alan Wayne 301-496-4256	Pediatric Oncology 1-877-624-4878 (Toll free)
Short-Course EPOCH-Rituximab in Untreated CD-20+ HIV-Associated Lymphomas NCI-01-C-0030	Wyndham H. Wilson 301-435-2415	Nicole Grant 301-594-2947 grantn@mail.nih.gov
Phase I/II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax®) in the Therapy of Tac-Expressing Adult T-Cell Leukemia NCI-00-C-0030	John C. Morris 301-402-2912	Suzanne Fioravanti 301-594-6544 fioravas@mail.nih.gov

For additional studies that may be appropriate for your disease type, please search under Solid Tumor.